ClinicalTrials.Veeva

Menu

Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock

University of Minnesota (UMN) logo

University of Minnesota (UMN)

Status

Enrolling

Conditions

Acute Coronary Syndrome
Cardiogenic Shock

Treatments

Other: Physiological Assessment

Study type

Observational

Funder types

Other

Identifiers

NCT05426083
CV-2022-30951

Details and patient eligibility

About

A Clinical Events Committee (CEC) will include Cardiac Surgery Professor and chief of cardiac surgery Rose Kelly MD, Professor of Medicine Ganesh Raveendran MD at the University of Minnesota who is the direction of Interventional Cardiology and Professor of Medicine at the University of Minnesota David Benditt. They will review and adjudicate serious and unexpected adverse events independently from the PI and co investigators.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18-75 years
  • SCAI D/E CS requiring VA-ECMO support based on treating team's judgement.
  • MAP >65 mmHg on <3 vasopressors/inotropes at the time of consent
  • Cardiogenic shock due to acute coronary syndrome identified by coronary angiography at the index hospitalization per standard cardiology practice

Exclusion criteria

  • VA-ECMO for sepsis, pulmonary embolism, COVID-19 related cardiorespiratory failure, severe RV failure due to severe idiopathic pulmonary hypertension
  • CS due to other (non-ACS) etiologies
  • Known patient with severe left ventricular dysfunction and stage IV NYHA heart failure being evaluated for or with a history of LVAD and transplantation prior to commencement of VA-ECMO
  • Profound vasoplegia with MAP <65 mmHg on 3 vasopressors/inotropes
  • Moderate to severe aortic regurgitation (contraindication to VA-ECMO)
  • Moderate to severe aortic stenosis (contraindication to LV instrumentation with PV loop catheter)
  • Bleeding complications requiring ongoing transfusions of blood products
  • Ischemic lower extremities
  • Evidence of circuit thrombosis or fibrin accumulation (turndown increases risk for stroke and clot formation)
  • Evidence of sepsis or septic shock
  • Evidence of LV thrombus on echocardiography (contraindication for accessing LV cavity with catheters)

Trial design

200 participants in 1 patient group

Physiological Assessment
Description:
Prospective physiological assessment of LV work and oxygen consumption in patients with SCAI D/E cardiogenic shock due to acute coronary syndrome treated with peripheral VA-ECMO support.
Treatment:
Other: Physiological Assessment

Trial contacts and locations

1

Loading...

Central trial contact

Julie Longman

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems